¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2021³â ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ Ãß°èÇмú´ëȸ ¹× ¿¬¼ö±³À° : 2021-10-01

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
2021³â ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ Ãß°èÇмú´ëȸ ¹× ¿¬¼ö±³À° : 2021-10-01
±³À°ÀÏÀÚ : 2021-10-01
±³À°Àå¼Ò : ¼­¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ ¹× ´ëȸÀǽǠ 
±³À°ÁÖÁ¦ : 2021³â ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ Ãß°èÇмú´ëȸ ¹× ¿¬¼ö±³À°
ÁÖÃÖ±â°ü : ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ
´ã´çÀÚ : À̼¼Àº
¿¬¶ôó : 02-784-2742  
À̸ÞÀÏ : secretariat@kcnp.or.kr      
±³À°Á¾·ù : Á¤½Å°Ç°­ÀÇÇаú      
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 4Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 7 ½Ã°£ 35ºÐ  
¼¼ºÎ¼ö°­·á : 40,000¿ø      
ºñ°í »çÀüµî·Ïºñ Æò»ýȸ¿ø ¸éÁ¦/Á¤È¸¿ø 20,000¿ø/ºñȸ¿ø 30,000¿ø/ÁØȸ¿ø¹×±âŸ 10,000¿ø/´çÀϵî·Ïºñ Æò»ýȸ¿ø 10,000¿ø/Á¤È¸¿ø 30,000¿ø/ºñȸ¿ø 40,000¿ø/ÁØȸ¿ø ¹× ±âŸ 20,000¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 10-01 ÄÁº¥¼ÇȦ 13:25~13:50 Efficacy of Duloxetine on depression and pain in cancer patients  Á¤Á¾Çö(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 10-01 ´ëȸÀǽǠ13:00~13:50 Reliable long-term management that prevents recurrences and preserves functioning in bipolar disorder  Àå½ÂÈ£(¿ø±¤ÀÇ´ë) 
Åä·Ð 10-01 ÄÁº¥¼ÇȦ 13:50~14:05 Consensus of definition of TRD  ¼ºÇü¸ð/Àå¼¼Çå/¹Ú¿µ¹Î/±è¿ø(¼øõÇâÀÇ´ë/ºÀ»ýº´¿ø/ÀÎÁ¦ÀÇ´ë/ÀÎÁ¦ÀÇ´ë) 
Åä·Ð 10-01 ÄÁº¥¼ÇȦ 14:05~14:20 Pharmacological management for TRD  ¼ºÇü¸ð/Àå¼¼Çå/¹Ú¿µ¹Î/±è¿ø(¼øõÇâÀÇ´ë/ºÀ»ýº´¿ø/ÀÎÁ¦ÀÇ´ë/ÀÎÁ¦ÀÇ´ë) 
Åä·Ð 10-01 ÄÁº¥¼ÇȦ 14:20~14:40 Non-pharmacological management for TRD  ¼ºÇü¸ð/Àå¼¼Çå/¹Ú¿µ¹Î/±è¿ø(¼øõÇâÀÇ´ë/ºÀ»ýº´¿ø/ÀÎÁ¦ÀÇ´ë/ÀÎÁ¦ÀÇ´ë) 
±³À°½Ã°£ 10-01 ´ëȸÀǽǠ13:50~14:15 When could Vortioxetine be a relevant treatment option for patients with MDD living through the pandemic?  ÀÌ°­¼ö(Â÷ÀÇ°úÇдë) 
±³À°½Ã°£ 10-01 ´ëȸÀǽǠ14:15~14:40 Dose-response relationship among antidepressant treatment option and for Vortioxetine  ¿Õ¼º¹Î(°¡Å縯ÀÇ´ë) 
È޽Ġ10-01  14:40~14:55   () 
±³À°½Ã°£ 10-01 ÄÁº¥¼ÇȦ 14:55~15:20 Eye-contact game using mixed reality for the treatment of children with attention deficit hyperactivity disorder  ±è±â¹ü(ÇѾç´ë ¿¡¸®Ä« ¼ÒÇÁÆ®¿þ¾î À¶ÇÕ´ëÇÐ) 
±³À°½Ã°£ 10-01 ÄÁº¥¼ÇȦ 15:20~15:45 Virtual school and VR game addiction treatment program for adolescents and young adults  ±èÀºÁÖ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 10-01 ÄÁº¥¼ÇȦ 15:45~16:05 Are digital therapeutics appropriate for individuals with ASD?  À¯ÈñÁ¤(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 10-01 ´ëȸÀǽǠ14:55~15:20 Homeostasis and allostasis  ÀüÈ«ÁØ(°Ç±¹ÀÇ´ë) 
±³À°½Ã°£ 10-01 ´ëȸÀǽǠ15:20~15:45 Allostasis in addiction  Á¤¿µÃ¶(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 10-01 ´ëȸÀǽǠ15:45~16:05 Allostasis in mood disorder  ³ë´ë¿µ(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 10-01 ÄÁº¥¼ÇȦ 16:05~16:30 Classic pharmacotherapy for AD and its limitations  ÀÓÇö±¹(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 10-01 ÄÁº¥¼ÇȦ 16:30~16:55 Amyloid-¥â/tau-targeting immunotherapy and its limitations  ¼­½Â¿Ï(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 10-01 ÄÁº¥¼ÇȦ 16:55~17:15 Newly approved drug: Aducanumab  ¾öÀ¯Çö(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 10-01 ´ëȸÀǽǠ16:05~16:30 Pathophysiology in postpartum depression  ÀÓÀº¼º(½Å¼¼°èÈ¿º´¿ø) 
±³À°½Ã°£ 10-01 ´ëȸÀǽǠ16:30~16:55 Prevention and risk factor control for PPD  °­ÇÑ°íÀººñ(±¹¸³³ªÁÖº´¿ø) 
±³À°½Ã°£ 10-01 ´ëȸÀǽǠ16:55~17:15 Allopregnanolone in PPD: Brexanolone  È«Á¤¿Ï(Àͻ꺴¿ø) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2021³â ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ Ãß°èÇмú´ëȸ ¹× ¿¬¼ö±³À° : 2021-10-01""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2021 ÃæûºÏµµ³»°úÀÇ»çȸ Ãß°èÇмú´ëȸ : 2021-10-02
´ÙÀ½±Û (¿Â¶óÀÎ) ¼Ò¾Æû¼Ò³â°ú ÀÏÂ÷ÀǷῬ±¸È¸ ¿Â¶óÀÎ Áý´ãȸ-¼Ò¾Æ ¾ð¾îÁö¿¬ Æò°¡, ¼Ò¾Æ ¹ß´Þ°ú Çൿ ÀÌ·Ð : 2021-09-29
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20694 ´ëÀü Á¦8ȸ ³»ºÐºñ ÃÊÀ½ÆÄ ¹× ±â´É°Ë»ç ¿¬¼ö°­Á : 2024-06-29 0 56 2024-05-11
20693 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 4Â÷ : 2024-06-29 0 38 2024-05-11
20692 ¼­¿ï Á¦24ȸ ´ëÇÑÀ¯Àü¼º´ë»çÁúȯÇÐȸ Á¤±âÇмú´ëȸ : 2024-06-28 0 39 2024-05-11
20691 °æ±â Á¤½Å°Ç°­ÀÇÇаú ÀÓ»ó¿¡¼­ À¯¿ëÇÑ Ä¡·á¹ý : 2024-06-26 0 51 2024-05-11
20690 ¼­¿ï (¿Â¶óÀÎ)2024 ÇѾç´ëÇб³º´¿ø È£Èí±â¾Ë·¹¸£±â ¿¬¼ö°­Á : 2024-06-22 0 40 2024-05-11
20689 ºÎ»ê °í½Å´ëÇб³º¹À½º´¿ø Á¦20ȸ °©»ó¼±¿¬¼öȸ : 2024-06-22 0 36 2024-05-11
20688 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 3Â÷ : 2024-06-22 0 13 2024-05-11
20687 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (2ÀÏÂ÷) : 2024-06-22 0 14 2024-05-11
20686 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 2 : 2024-06-21 0 33 2024-05-11
20685 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (1ÀÏÂ÷) : 2024-06-21 0 16 2024-05-11
20684 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 1 : 2024-06-20 0 15 2024-05-11
20683 ¼­¿ï ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ (¿Â¶óÀÎ) ¼­¿ï°æÀÎÁöȸ 277Â÷ ¿ù·ÊÁý´ãȸ : 2024-06-18 0 35 2024-05-11
20682 ¼­¿ï 2024 °­µ¿±¸ÀÇ»çȸ Á¦3Â÷ ¿¬¼ö±³À°(¿°Áõ¼º ÀåÁúȯ,ºñ¸¸ ¾à¹° Ä¡·á ) : 2024-06-17 0 26 2024-05-11
20681 ¼­¿ï ´ëÇÑ´ç´¢º´ÇÐȸ Á¦29Â÷ ´ç´¢º´ ¿¬¼ö°­Á : 2024-06-16 0 31 2024-05-11
20680 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 2Â÷ : 2024-06-15 0 24 2024-05-11
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷